- AU$6.98m
- AU$8.23m
- AU$4.53m
Brief: Hungary's Richter and Acrux agree to license transdermal Estradiol spray for Australia
Brief: Acrux Says Capital Gains Tax Exemptions Remain In Place For Acrux
Australia's Acrux jumps on placement to fund female testosterone program
Brief: Acrux Raises A$1.6 Mln Via At 0.95 AU Cents Per Share
Brief: Acrux Requests Trading Halt
Brief: Acrux Ltd Pots FY Loss Attributable Of A$5.9 Million
Brief: Acrux Signs Agreement With Servacure For Dapsone Gel In Saudi Arabia
Brief: Acrux Ltd Appoints John Warmbrunn As CEO And Managing Director
Brief: Acrux Ltd Says CEO Michael Kotsanis Announced Retirement
Brief: Acrux Ltd Raises A$1.34 Mln From Share Purchase Plan
Brief: Acrux Says Share Placement Concluded
US FDA Approves Nitroglycerin Ointment
Brief: Acrux Ltd Seeks Trading Halt
Australia's Acrux soars on US FDA approval for acne treatment gel
Brief: Acrux Ltd Says Received FDA Approval For Generic Version Of Aczone Gel
Australia's Acrux eyes best day on US product launch
Australia's Acrux rises on hormonal product ownership even after deal termination
Brief: Acrux Ltd And Dash Pharmaceuticals Mutually Terminate Commercialisation Agreement
Acrux eyes best day in 3 wks on US FDA nod for new drug application